Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Recruiting · NCT06589440 · Registry updated 2026-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Recruiting | Phase 2 | 2026-08-12 | NCT06589440 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Stingray Therapeutics | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atlantic Health | Morristown | United States | 10 |
| Swedish | Seattle | United States | 1 |
| Texas Oncology- Austin | Austin | United States | 2 |
| Texas Oncology- Northeast Texas | Tyler | United States | 6 |
| Texas Oncology- Sammons- DFW | Dallas | United States | 1 |
| The University of Texas M.D. Anderson Cancer Center GI Medical Oncology Dept | Houston | United States | 1 |